Supporting the potential of OC2 as a therapeutic target in aggressive BC disease, in three separate cohorts [38, 46, 47] OC2 mRNA expression is significantly higher in BC specimens from patients that exhibited recurrence compared to patients that remained disease-free (Fig. 6E–G). Here, ONECUT2 is linked to breast cancer.